Merus Labs International (Merus Labs International) Debt-to-Equity : 0.73 (As of Mar. 2017)

View and export this data going back to 1996. Start your Free Trial

What is Merus Labs International Debt-to-Equity?

Merus Labs International's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2017 was $31.55 Mil. Merus Labs International's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2017 was $70.01 Mil. Merus Labs International's Total Stockholders Equity for the quarter that ended in Mar. 2017 was $140.06 Mil. Merus Labs International's debt to equity for the quarter that ended in Mar. 2017 was 0.73.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Merus Labs International's Debt-to-Equity or its related term are showing as below:

MSLI's Debt-to-Equity is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.28
* Ranked among companies with meaningful Debt-to-Equity only.

Merus Labs International Debt-to-Equity Historical Data

The historical data trend for Merus Labs International's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merus Labs International Debt-to-Equity Chart

Merus Labs International Annual Data

Trend

Sep07

Sep08

Sep09

Sep10

Sep11

Sep12

Sep13

Sep14

Sep15

Sep16

Debt-to-Equity

Get a 7-Day Free Trial

1.53

0.87

0.75

0.35

0.76

Merus Labs International Quarterly Data
	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17
Debt-to-Equity	Get a 7-Day Free Trial															0.82	0.79	0.76	0.75	0.73

Competitive Comparison of Merus Labs International's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Merus Labs International's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Merus Labs International's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Merus Labs International's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Merus Labs International's Debt-to-Equity falls into.

Merus Labs International Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Merus Labs International's Debt to Equity Ratio for the fiscal year that ended in Sep. 2016 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(31.332	+	83.151)	/	150.874
	=	0.76

Merus Labs International's Debt to Equity Ratio for the quarter that ended in Mar. 2017 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(31.549	+	70.013)	/	140.055
	=	0.73

Merus Labs International (NAS:MSLI) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Merus Labs International Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Merus Labs International's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Merus Labs International (Merus Labs International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Merus Labs International Inc (NAS:MSLI) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.meruslabs.com

Merus Labs International Inc was incorporated on October 1, 2012 in British Columbia. The Company is a specialty pharmaceutical company. It acquires prescription medicines in various categories which include on patent but at maturity stage of product life cycle; branded generics; under promoted products; Niche market pharmaceuticals; and products with annual sales below critical threshold for large pharma. The Company competes with multinational pharmaceutical development corporations to small, single product companies that may limit their activities to a particular therapeutic area or region or territory.

Merus Labs International (Merus Labs International) Headlines

From GuruFocus

Slow Growth Ahead; Updates on Merus Labs International, Enghouse Systems, Athabasca Minerals

By Gordon Pape Gordon Pape • 10-05-2015

Update on Merus Labs International, Athabasca Minerals Inc, Enghouse Systems Limited, WiLAN Inc.

By Gordon Pape Gordon Pape • 06-22-2015

Merus Labs International: A Pharma Stock With Growth Potential

By Gordon Pape Gordon Pape • 03-30-2015